Search Results - "Clinical cancer research"

eJournal

Clinical cancer research

related American Association for Cancer Research

Volume available online?

Journal

Clinical cancer research: an official journal of the American Association for Cancer Research

related American Association for Cancer Research ¬[Herausgebendes Organ]

Holdings Uni Bonn

Journal Article

Journal of experimental and clinical cancer research [electronic resource] : CR

by National Institutes of Health (U.S.). PubMed Central
Published in Journal of experimental & clinical cancer research

Journal Article

Clinical cancer research [electronic resource]

by HighWire Press American Association for Cancer Research
Published in Clinical cancer research

Journal Article

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

by Champiat, Stéphane Dercle, Laurent Ammari, Samy Massard, Christophe Hollebecque, Antoine Postel-Vinay, Sophie Chaput, Nathalie Eggermont, Alexander Marabelle, Aurélien Soria, Jean-Charles Ferté, Charles Published in Clinical cancer research (15.04.2017)

“...While immune checkpoint inhibitors are disrupting the management of patients with cancer, anecdotal occurrences of rapid progression (i.e., hyperprogressive...”

Fulltext

Journal Article

EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis

by Gainor, Justin F Shaw, Alice T Sequist, Lecia V Fu, Xiujun Azzoli, Christopher G Piotrowska, Zofia Huynh, Tiffany G Zhao, Ling Fulton, Linnea Schultz, Katherine R Howe, Emily Farago, Anna F Sullivan, Ryan J Stone, James R Digumarthy, Subba Moran, Teresa Hata, Aaron N Yagi, Yukako Yeap, Beow Y Engelman, Jeffrey A Mino-Kenudson, Mari Published in Clinical cancer research (15.09.2016)

“...PD-1 inhibitors are established agents in the management of non-small cell lung cancer (NSCLC); however, only a subset of patients derives clinical benefit. To...”

Fulltext

Journal Article

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

by Taube, Janis M Klein, Alison Brahmer, Julie R Xu, Haiying Pan, Xiaoyu Kim, Jung H Chen, Lieping Pardoll, Drew M Topalian, Suzanne L Anders, Robert A Published in Clinical cancer research (01.10.2014)

“...Immunomodulatory drugs differ in mechanism-of-action from directly cytotoxic cancer therapies. Identifying factors predicting clinical response could guide...”

Fulltext

Journal Article

Hyperprogressors after immunotherapy: Analysis of genomic alterations associated with accelerated growth rate

by Kato, Shumei Goodman, Aaron Walavalkar, Vighnesh Barkauskas, Donald A Sharabi, Andrew Kurzrock, Razelle Published in Clinical cancer research (01.08.2017)

“...Checkpoint inhibitors demonstrate salutary anticancer effects, including long-term remissions. PD-L1 expression/amplification, high mutational burden, and...”

Fulltext

Journal Article

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

by Ren, Jiangtao Liu, Xiaojun Fang, Chongyun Jiang, Shuguang June, Carl H Zhao, Yangbing Published in Clinical cancer research (01.05.2017)

“...Using gene-disrupted allogeneic T cells as universal effector cells provides an alternative and potentially improves current chimeric antigen receptor (CAR)...”

Fulltext

Journal Article

PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression

by Jiao, Shiping Xia, Weiya Yamaguchi, Hirohito Wei, Yongkun Chen, Mei-Kuang Hsu, Jung-Mao Hsu, Jennifer L Yu, Wen-Hsuan Du, Yi Lee, Heng-Huan Li, Chia-Wei Chou, Chao-Kai Lim, Seung-Oe Chang, Shih-Shin Litton, Jennifer Arun, Banu Hortobagyi, Gabriel N Hung, Mien-Chie Published in Clinical cancer research (15.07.2017)

“...To explore whether a cross-talk exists between PARP inhibition and PD-L1/PD-1 immune checkpoint axis, and determine whether blockade of PD-L1/PD-1 potentiates...”

Fulltext

Journal Article

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

by Freeman-Keller, Morganna Kim, Youngchul Cronin, Heather Richards, Allison Gibney, Geoffrey Weber, Jeffrey S Published in Clinical cancer research (15.02.2016)

“...Retrospective analysis of irAEs in melanoma patients treated with nivolumab. Data were pooled from 148 patients (33 resected, 115 unresectable) treated with...”

Fulltext

Journal Article

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

by YU, Helena A ARCILA, Maria E REKHTMAN, Natasha SIMA, Camelia S ZAKOWSKI, Maureen F PAO, William KRIS, Mark G MILLER, Vincent A LADANYI, Marc RIELY, Gregory J Published in Clinical cancer research (2013)

“...All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI). Smaller series have...”

Fulltext

Journal Article

Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity

by Ballard, Peter Yates, James W T Yang, Zhenfan Kim, Dong-Wan Yang, James Chih-Hsin Cantarini, Mireille Pickup, Kathryn Jordan, Angela Hickey, Mike Grist, Matthew Box, Matthew Johnström, Peter Varnäs, Katarina Malmquist, Jonas Thress, Kenneth S Jänne, Pasi A Cross, Darren Published in Clinical cancer research (15.10.2016)

“...Approximately one-third of patients with non-small cell lung cancer (NSCLC) harboring tumors with EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations...”

Fulltext

Journal Article

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

by Dong, Zhong-Yi Zhong, Wen-Zhao Zhang, Xu-Chao Su, Jian Xie, Zhi Liu, Si-Yang Tu, Hai-Yan Chen, Hua-Jun Sun, Yue-Li Zhou, Qing Yang, Jin-Ji Yang, Xue-Ning Lin, Jia-Xin Yan, Hong-Hong Zhai, Hao-Ran Yan, Li-Xu Liao, Ri-Qiang Wu, Si-Pei Wu, Yi-Long Published in Clinical cancer research (15.06.2017)

“...Although clinical studies have shown promise for targeting programmed cell death protein-1 (PD-1) and ligand (PD-L1) signaling in non-small cell lung cancer...”

Fulltext

Journal Article

Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

by Burstein, Matthew D Tsimelzon, Anna Poage, Graham M Covington, Kyle R Contreras, Alejandro Fuqua, Suzanne A W Savage, Michelle I Osborne, C Kent Hilsenbeck, Susan G Chang, Jenny C Mills, Gordon B Lau, Ching C Brown, Powel H Published in Clinical cancer research (01.04.2015)

“...Genomic profiling studies suggest that triple-negative breast cancer (TNBC) is a heterogeneous disease. In this study, we sought to define TNBC subtypes and...”

Fulltext

Journal Article

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

by Weide, Benjamin Martens, Alexander Hassel, Jessica C Berking, Carola Postow, Michael A Bisschop, Kees Simeone, Ester Mangana, Johanna Schilling, Bastian Di Giacomo, Anna Maria Brenner, Nicole Kaehler, Katharina Heinzerling, Lucie Gutzmer, Ralf Bender, Armin Gebhardt, Christoffer Romano, Emanuela Meier, Friedegund Martus, Peter Maio, Michele Blank, Christian Schadendorf, Dirk Dummer, Reinhard Ascierto, Paolo A Hospers, Geke Garbe, Claus Wolchok, Jedd D Published in Clinical cancer research (15.11.2016)

“...Purpose: Biomarkers for outcome after immune-checkpoint blockade are strongly needed as these may influence individual treatment selection or sequence. We...”

Fulltext

Journal Article

Microsatellite Instability as a Biomarker for PD-1 Blockade

by Dudley, Jonathan C Lin, Ming-Tseh Le, Dung T Eshleman, James R Published in Clinical cancer research (15.02.2016)

“...Initial results by Le and colleagues, which were published in the June 25, 2015 issue of the New England Journal of Medicine, report significant responses of...”

Fulltext

Journal Article

Circular RNA ciRS-7-A promising prognostic biomarker and a potential therapeutic target in colorectal cancer

by Weng, Wenhao Wei, Qing Toden, Shusuke Yoshida, Kazuhiro Nagasaka, Takeshi Fujiwara, Toshiyoshi Cai, Sanjun Qin, Huanlong Ma, Yanlei Goel, Ajay Published in Clinical cancer research (15.07.2017)

“...Colorectal cancer is one of the most common malignancies worldwide. Recently, a novel circular RNA, ciRS-7, was proposed to be a potential miR-7 sponge. As...”

Fulltext

Journal Article

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

by Marcus, Leigh Lemery, Steven J Keegan, Patricia Pazdur, Richard Published in Clinical cancer research (01.07.2019)

“...The FDA approved pembrolizumab on May 23, 2017, for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite...”

Fulltext

Journal Article

Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors

by Patnaik, Amita Kang, S Peter Rasco, Drew Papadopoulos, Kyriakos P Elassaiss-Schaap, Jeroen Beeram, Muralidhar Drengler, Ronald Chen, Cong Smith, Lon Espino, Guillermo Gergich, Kevin Delgado, Liliana Daud, Adil Lindia, Jill A Li, Xiaoyun Nicole Pierce, Robert H Yearley, Jennifer H Wu, Dianna Laterza, Omar Lehnert, Manfred Iannone, Robert Tolcher, Anthony W Published in Clinical cancer research (01.10.2015)

“...This phase I study evaluated the safety, maximum tolerated dose, antitumor activity, and pharmacokinetics and pharmacodynamics of pembrolizumab in patients...”

Fulltext

1
2
3
4
5
6
7
8
9
10
11
Next »
[50]

Narrow search